Baseline and early changes in circulating Serum Amyloid A (SAA) predict survival outcomes in advanced non-small cell lung cancer patients treated with Anti-PD-1/PD-L1 monotherapy

Blumenthal, 2017, Milestone analyses of immune checkpoint inhibitors, targeted therapy, and conventional therapy in metastatic non-small cell lung cancer trials: a meta-analysis, JAMA Oncol., 3, 10.1001/jamaoncol.2017.1029 Rittmeyer, 2017, Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial, Lancet, 389, 255, 10.1016/S0140-6736(16)32517-X Antonia, 2019, Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis, Lancet Oncol., 20, 1395, 10.1016/S1470-2045(19)30407-3 Herbst, 2020, Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1‒positive, advanced non‒small-cell lung cancer in the KEYNOTE-010 study, J. Clin. Oncol., 38, 1580, 10.1200/JCO.19.02446 Diakos, 2014, Cancer-related inflammation and treatment effectiveness, Lancet Oncol., 15, e493, 10.1016/S1470-2045(14)70263-3 Mantovani, 2008, Cancer-related inflammation, Nature, 454, 436, 10.1038/nature07205 Hussain, 2007, Inflammation and cancer: an ancient link with novel potentials, Int. J. Cancer, 121, 2373, 10.1002/ijc.23173 Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 Kanterman, 2012, New insights into chronic inflammation-induced immunosuppression, Semin. Cancer Biol., 22, 307, 10.1016/j.semcancer.2012.02.008 Smyth, 2016, Combination cancer immunotherapies tailored to the tumour microenvironment, Nat. Rev. Clin. Oncol., 13, 143, 10.1038/nrclinonc.2015.209 Nakamura, 2017, Targeting cancer-related inflammation in the era of immunotherapy, Immunol. Cell Biol., 95, 325, 10.1038/icb.2016.126 Nakaya, 2018, Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab, Int. J. Clin. Oncol., 23, 634, 10.1007/s10147-018-1250-2 Fidler, 2018, The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients, BMC Cancer, 18, 310, 10.1186/s12885-018-4193-0 Hopkins, 2020, Development and validation of a prognostic model for patients with advanced lung cancer treated with the immune checkpoint inhibitor atezolizumab, Clin. Cancer Res., 26, 3280, 10.1158/1078-0432.CCR-19-2968 Iivanainen, 2019, Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors, ESMO Open, 4, 10.1136/esmoopen-2019-000531 Yildiz, 2007, Diagnostic accuracy of MALDI mass spectrometric analysis of unfractionated serum in lung cancer, J. Thorac. Oncol., 2, 893, 10.1097/JTO.0b013e31814b8be7 De Santo, 2010, Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A, Nat. Immunol., 11, 1039, 10.1038/ni.1942 Kanoh, 2013, Progression of non-small cell lung cancer: diagnostic and prognostic utility of matrix metalloproteinase-2, C-reactive protein and serum amyloid A, Oncol. Rep., 29, 469, 10.3892/or.2012.2123 Cho, 2010, Serum amyloid A is elevated in the serum of lung cancer patients with poor prognosis, Br. J. Cancer, 102, 1731, 10.1038/sj.bjc.6605700 Milan, 2012, SAA1 is over-expressed in plasma of non small cell lung cancer patients with poor outcome after treatment with epidermal growth factor receptor tyrosine-kinase inhibitors, J. Proteomics, 76 Zhang, 2015, The prognostic value of serum C-reactive protein-bound serum amyloid A in early-stage lung cancer, Chin. J. Cancer, 34, 335, 10.1186/s40880-015-0039-1 Camp, 2004, X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization, Clin. Cancer Res., 10, 7252, 10.1158/1078-0432.CCR-04-0713 Gomes, 2014, The role of inflammation in lung cancer, Adv. Exp. Med. Biol., 816, 1, 10.1007/978-3-0348-0837-8_1 Sack, 2018, Serum amyloid A - a review, Mol Med, 24, 46, 10.1186/s10020-018-0047-0 Ye, 2015, Emerging functions of serum amyloid A in inflammation, J. Leukoc. Biol., 98, 923, 10.1189/jlb.3VMR0315-080R Toriola, 2013, Biomarkers of inflammation are associated with colorectal cancer risk in women but are not suitable as early detection markers, Int. J. Cancer, 132, 2648, 10.1002/ijc.27942 Vermaat, 2012, Validation of serum amyloid α as an independent biomarker for progression-free and overall survival in metastatic renal cell cancer patients, Eur. Urol., 62, 685, 10.1016/j.eururo.2012.01.020 Shiels, 2015, Circulating inflammation markers, risk of lung cancer, and utility for risk stratification, J. Natl. Cancer Inst., 107 Sasazuki, 2010, Plasma levels of C-reactive protein and serum amyloid A and gastric cancer in a nested case-control study: Japan Public Health Center-based prospective study, Carcinogenesis, 31, 712, 10.1093/carcin/bgq010 Li, 2020, The prognostic value of integration of pretreatment serum amyloid A (SAA)-EBV DNA (S-D) grade in patients with nasopharyngeal carcinoma, Clin. Transl. Med., 9, 2, 10.1186/s40169-019-0252-7 Bobin-Dubigeon, 2015, Paired measurement of serum amyloid A (SAA) and paraoxonase 1 (PON1) as useful markers in breast cancer recurrence, Clin. Biochem., 48, 1181, 10.1016/j.clinbiochem.2015.07.020 Van Cutsem, 2020, Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study, Eur. J. Cancer, 127, 150, 10.1016/j.ejca.2019.10.026 Findeisen, 2009, Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling, J. Clin. Oncol., 27, 2199, 10.1200/JCO.2008.18.0554 Moshkovskii, 2012, Why do cancer cells produce serum amyloid A acute-phase protein?, Biochemistry (Mosc.), 77, 339, 10.1134/S0006297912040037 Wang, 2017, Ubiquitination of tumor suppressor PML regulates prometastatic and immunosuppressive tumor microenvironment, J. Clin. Invest., 127, 2982, 10.1172/JCI89957 Lee, 2014, Serum amyloid A3 exacerbates cancer by enhancing the suppressive capacity of myeloid-derived suppressor cells via TLR2-dependent STAT3 activation, Eur. J. Immunol., 44, 1672, 10.1002/eji.201343867 Di Noia, 2020, Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory “FoRECATT” study, Cancer Immunol. Immunother. Raynes, 1983, Comparison of serum amyloid A protein and C-reactive protein concentrations in cancer and non-malignant disease, J. Clin. Pathol., 36, 798, 10.1136/jcp.36.7.798 Bagley, 2017, Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer, Lung Cancer, 106, 1, 10.1016/j.lungcan.2017.01.013 Bartlett, 2020, High neutrophil-to-lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD-1 inhibitor monotherapy, Cancer, 126, 76, 10.1002/cncr.32506